NCT03321981: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer

NCT03321981
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: If HR+/HER2-negative, must also be ER+
Exclusions: Central nervous system metastases that are untreated or symptomatic; Known leptomeningeal involvement- see trial for details
https://ClinicalTrials.gov/show/NCT03321981

Comments are closed.

Up ↑